Patrick O'Brien sold $3.1M of ARWR
COO at ARROWHEAD PHARMACEUTICALS, INC.. 49,493 shares at an average of $63.11, traded Jan 5, 2026, filed Jan 5, 2026.
Score components
- +20RoleCOO
- +25Trade size$3.1M at market
- 0Share of holdings soldSold 9.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001627183-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 526,641 | Jan 5, 2026 |
| Dec 31, 2025 | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 526,081 | Jan 5, 2026 |
| Dec 31, 2025 | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 525,521 | Jan 5, 2026 |
| Dec 31, 2025 | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 524,961 | Jan 5, 2026 |
| Dec 31, 2025 | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 524,401 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -4,368 | $61.20 | $267k | 520,033 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -6,164 | $62.23 | $384k | 513,869 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -13,451 | $62.96 | $847k | 500,418 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -11,842 | $63.84 | $756k | 488,576 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -2,700 | $64.44 | $174k | 485,876 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -900 | $66.01 | $59k | 484,976 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -313 | $68.00 | $21k | 484,663 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $61.12 | $37k | 484,063 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -900 | $62.25 | $56k | 483,163 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -5,873 | $62.91 | $369k | 477,290 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -2,336 | $64.04 | $150k | 474,954 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -46 | $68.00 | $3,128 | 474,908 | Jan 5, 2026 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% | |
| 28Weak | ARROWHEAD PHARMACEUTICALS, INC. | Mauro Ferrari director | $527k 7,530 shares | -10% | |
| 35Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $677k 10,000 shares | -23% | |
| 45Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $1.8M 26,031 shares | -1% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | William D. Waddill director | $566k 8,367 shares | -13% | |
| 36Weak | ARROWHEAD PHARMACEUTICALS, INC. | Victoria Vakiener director | $679k 10,040 shares | -22% | |
| 65Notable | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $5.4M 85,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.